Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)

• Company Description    Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Number of Employees: 1,294

• Price / Volume Information    Yesterday's Closing Price: $39.91 Daily Weekly Monthly 20 Day Moving Average: 1,067,659 shares Shares Outstanding: 94.54 (millions) Market Capitalization: $3,773.17 (millions) Beta: 0.26 52 Week High: $60.37 52 Week Low: $29.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.13% 2.27% 12 Week 20.36% 0.97% Year To Date -5.13% -11.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 Leveroni Court - Novato,CA 94949 USA ph: 415-483-8800 fax: 415-483-8810 ir@ultragenyx.com http://www.ultragenyx.com

• General Corporate Information    Officers Emil D. Kakkis - President and Chief Executive Officer Daniel G. Welch - Chairman Howard Horn - Executive Vice President; Chief Financial Officer; Theodore A. Huizenga - Senior Vice President and Chief Accounting Officer Deborah Dunsire - Director Peer Information Ultragenyx Pharmaceutical Inc. (CORR.) Ultragenyx Pharmaceutical Inc. (RSPI) Ultragenyx Pharmaceutical Inc. (CGXP) Ultragenyx Pharmaceutical Inc. (BGEN) Ultragenyx Pharmaceutical Inc. (GTBP) Ultragenyx Pharmaceutical Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90400D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 94.54 Most Recent Split Date: (:1) Beta: 0.26 Market Capitalization: $3,773.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.23 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 21.78% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 25.98 Price/Cash Flow: - Price / Sales: 6.39 EPS Growth vs. Year Ago Period: 22.66% vs. Previous Quarter: -12.95% Sales Growth vs. Year Ago Period: 27.99% vs. Previous Quarter: -15.52% ROE 06/30/25 - - 03/31/25 - -186.49 12/31/24 - -193.80 ROA 06/30/25 - - 03/31/25 - -36.81 12/31/24 - -38.15 Current Ratio 06/30/25 - - 03/31/25 - 2.40 12/31/24 - 2.37 Quick Ratio 06/30/25 - - 03/31/25 - 2.24 12/31/24 - 2.24 Operating Margin 06/30/25 - - 03/31/25 - -93.04 12/31/24 - -101.60 Net Margin 06/30/25 - - 03/31/25 - -93.04 12/31/24 - -101.60 Pre-Tax Margin 06/30/25 - - 03/31/25 - -92.62 12/31/24 - -101.31 Book Value 06/30/25 - - 03/31/25 - 1.54 12/31/24 - 2.76 Inventory Turnover 06/30/25 - - 03/31/25 - 2.01 12/31/24 - 1.87 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 4.63 12/31/24 - 2.67

Powered by Zacks Investment Research ©